Trials / Terminated
TerminatedNCT01795313
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
Immunotherapy for Recurrent Ependymomas in Children Using Human Leukocyte Antigen (HLA)-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- James Felker · Academic / Other
- Sex
- All
- Age
- 12 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas. Eligible patients are stratified by primary tumor location.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HLA-A2 restricted synthetic tumor antigen | |
| DRUG | Imiquimod | |
| OTHER | enzyme-linked immunosorbent assay | |
| OTHER | flow cytometry | |
| OTHER | immunohistochemistry staining method | |
| OTHER | laboratory biomarker analysis |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2025-12-03
- Completion
- 2025-12-03
- First posted
- 2013-02-20
- Last updated
- 2026-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01795313. Inclusion in this directory is not an endorsement.